Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNP-siVRMA
- Development stage
- Preclinical
- Lead developer
- Universidad de Navarra
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intramuscular, Subcutaneous, Oral, Inhalation, Intratumoral, Intracerebral, Intrauterine
01
Overview
LNP-siVRMA is a therapeutic agent comprising lipid nanoparticles (LNPs) encapsulating a small interfering RNA (siRNA) specifically designed to target and inhibit the expression of VRMA. VRMA is an N6-methyladenosine (m6A) regulatory gene found to be essential for the survival of Multiple Myeloma (MM) cells. By inhibiting VRMA, LNP-siVRMA aims to reduce global m6A levels, leading to G1 cell cycle arrest, reduced NF-κB signaling, and impaired mitochondrial respiration in MM cells, thereby suppressing tumor growth. This epitranscriptomic-based strategy represents a promising approach for treating MM.
02
Targets
VIRMA (Virilizer-like methyltransferase-associated protein)
Beyond the preview
Go deeper on LNP-siVRMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNP-siVRMA.